Cargando…

Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature

Risk assessment is critical to determine the timing of elective surgeries and preserve valuable resources in time of pandemic. This study was undertaken to better understand the potential value of molecular testing to risk‐stratify thyroid nodules with malignant cytology (Bethesda VI). Systematic re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labourier, Emmanuel, Fahey, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983887/ https://www.ncbi.nlm.nih.gov/pubmed/33052631 http://dx.doi.org/10.1002/dc.24637

Ejemplares similares

Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review
por: Hier, Jessica, et al.
Publicado: (2021)

Cytological diagnosis of pediatric thyroid nodule in perspective of the Bethesda System for Reporting Thyroid Cytopathology
por: Pantola, Chayanika, et al.
Publicado: (2016)

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
por: Almahari, Sayed Ali, et al.
Publicado: (2019)

Concordance between the TIRADS ultrasound criteria and the BETHESDA cytology criteria on the nontoxic thyroid nodule
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2017)

An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules
por: Taccogna, Silvia, et al.
Publicado: (2022)

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules
por: Hu, Mimi I, et al.
Publicado: (2021)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

Intraoperative frozen section can be reduced in thyroid nodules classified as Bethesda categories V and VI
por: Huang, Jing, et al.
Publicado: (2017)

Strain Elastography as a Valuable Diagnosis Tool in Intermediate Cytology (Bethesda III) Thyroid Nodules
por: Stoian, Dana, et al.
Publicado: (2019)

Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature
por: Alshaikh, Safa, et al.
Publicado: (2018)

Prediction of cytology–histology discrepancy when Bethesda cytology reports benign results for thyroid nodules in women: with special emphasis on pregnancy
por: Firat, Aysun, et al.
Publicado: (2023)

Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management
por: Chiosea, Simion, et al.
Publicado: (2023)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype
por: Yoo, Won Sang, et al.
Publicado: (2020)

Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis
por: Canberk, Sule, et al.
Publicado: (2022)

Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

Indeterminate Thyroid Nodules: From Cytology to Molecular Testing
por: Vignali, Paola, et al.
Publicado: (2023)

Review of atypical cytology of thyroid nodule according to the Bethesda system and its beneficial effect in the surgical treatment of papillary carcinoma
por: Chung, Yoo Seung, et al.
Publicado: (2011)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Thyroid Nodules Cytopathology Applying the Bethesda System with Histopathological Correlation
por: Zarif, Hawazen A., et al.
Publicado: (2018)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results
por: Chiang, Pi-Ling, et al.
Publicado: (2023)

Managing Bethesda IV thyroid nodules in an iodine-deficient population
por: Badash, Ido, et al.
Publicado: (2023)

Association of patient characteristics, ultrasound features, and molecular testing with malignancy risk in Bethesda III–V thyroid nodules
por: Talmor, Guy, et al.
Publicado: (2022)

Association of thiol/disulphide homeostasis with Bethesda classification of thyroid nodules and thyroid cancer
por: BİLGİNER, Muhammet Cüneyt, et al.
Publicado: (2022)

Incidence and Malignancy Rates of Diagnoses in the Bethesda System for Reporting Thyroid Aspiration Cytology: An Institutional Experience
por: Park, Ji Hye, et al.
Publicado: (2014)

Evaluation of selected ultrasound features of thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance for the Bethesda reporting system for thyroid cytology
por: Kaliszewski, Krzysztof, et al.
Publicado: (2018)

The Bethesda System for reporting cervical cytology
por: Pangarkar, Meena A.
Publicado: (2022)

Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
por: Penna, Gustavo Cancela e, et al.
Publicado: (2021)

Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
por: Kim, Na Eun, et al.
Publicado: (2023)

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital
por: Al Dawish, Mohamed, et al.
Publicado: (2020)

The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules()
por: Alqahtani, Saad M., et al.
Publicado: (2022)

Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology
por: Yaprak Bayrak, Busra, et al.
Publicado: (2020)

Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules
por: Dharampal, Navjit, et al.
Publicado: (2022)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

The Role of “Critical” Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules
por: Orlando, Giuseppina, et al.
Publicado: (2023)

Malignancy risk in Bethesda class IV thyroid nodules in an iodine deficient region
por: Loderer, Tommaso, et al.
Publicado: (2023)

A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology
por: Kloos, Richard T., et al.
Publicado: (2016)

Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules
por: Polavarapu, Preethi, et al.
Publicado: (2021)

Retrospective evaluation of frozen section use for thyroid nodules with a prior fine needle aspiration diagnosis of Bethesda II–VI: The Weill Cornell Medical College experience
por: Cohen, Marc A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rb0uq2q3k0d7tsiqndqb13o94t